FOR IMMEDIATE RELEASE Covington, KY ~ April 18, 2019
Bexion Pharmaceuticals, Inc., a clinical stage oncology company, announced today the initiation of an open-label Phase 1 Safety Study of BXQ-350. The first US site is Cincinnati Children’s Hospital Medical Center. This clinical trial will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in the pediatric population with recurrent solid tumors, brain tumors and diffuse intrinsic pontine gliomas (DIPG).
Phase 1 Adult Dose Ranging Study
In a Phase 1 Part 1 Adult Dose Ranging Study, BXQ-350 was well tolerated at all five doses tested with no dose limiting toxicities observed and no serious adverse events attributed to the therapy. Preliminary data in Part 2 of the Phase 1 support a safe and tolerable drug profile. Information about the Phase 1 Study of BXQ-350 in Adult Patients with Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857
Phase I Pediatric Protocol
In December 2018, the FDA cleared a Phase I Pediatric Protocol as part of Bexion’s current IND to move BXQ-350 into the pediatric population.
“With this initiation of Pediatric Phase 1 studies, we are confirming our commitment to the pediatric patient community,” stated Dr. Ray Takigiku, Founder and CEO of Bexion. “It is our goal to develop BXQ-350 as quickly as possible for both adult and pediatric cancer patients, particularly those with difficult to treat tumors including high grade gliomas and other brain tumors. We are very grateful to the patients, participating clinical trial sites, and our partners for their engagement and their support.”
Technology supporting BXQ-350 was discovered over 15 years ago
The technology supporting BXQ-350 was discovered over 15 years ago by Dr. Xiaoyang Qi, a then faculty member at Cincinnati Children’s. CancerFree KIDS, a non-profit focused on eradicating cancer a life-threatening disease in children, provided the first grant that supported this discovery. Cincinnati Children’s licensed the technology to Bexion to continue development and ultimately commercialize the discovery.
“The very first research grant CancerFree KIDS ever awarded was to Dr. Qi in 2004”, explained Ellen Flannery, Founder and Executive Director of CancerFree KIDS. “It was for the study that eventually led to the formation of Bexion Pharmaceuticals. We have followed this research and Bexion since that time, waiting for this pivotal moment of the initiation of a Pediatric Phase I trial. It is rare for a pediatric trial to happen so early in the development of a new treatment. CancerFree KIDS is grateful to Bexion, Cincinnati Children’s and CTI Clinical Trial and Consulting Services, Bexion’s Clinical Research Organization for initiating this trial as quickly as feasibly possible. This means we have an opportunity to get this extremely promising new treatment approved for the children who need it as quickly as possible.”
Additional Sites Are Planned
Additional sites are planned, including Nationwide Children’s Hospital in Columbus, Ohio and several children’s hospitals in the western United States.
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. BXQ-350 has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases. Bexion has completed multi-site first-in-human Phase 1 Parts 1 and 2 clinical studies of BXQ-350 for solid tumors and gliomas. A Phase 1 Part 3 expansion phase study is currently enrolling patients.
About CancerFree KIDS
The mission of CancerFree KIDS is to eradicate cancer as a life-threatening disease in children by funding promising research that might otherwise go unfunded. CancerFree KIDS was founded by Ellen and Sam Flannery after their baby daughter was diagnosed with cancer in both of her eyes at 5 months of age. Today, thanks to cancer research, that baby is a healthy college student. CancerFree KIDS funds childhood cancer research.
Media Contact: Margaret van Gilse ●859.757.1652 ● email@example.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Bexion’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Bexion has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Bexion’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that Bexion’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. You should not place undue reliance on any forward-looking statements. Bexion undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.